Based on the provided sources, it is not possible to determine the exact number of active patents for olaparib in the United States. The sources do not explicitly mention the number of patents specifically for olaparib. However, we can provide some information related to olaparib patents and its patent expiration.
Olaparib is a drug developed by AstraZeneca and is used for the treatment of certain types of ovarian and breast cancer. It belongs to a class of drugs called PARP inhibitors.
According to the first source, DrugPatentWatch, which provides information on pharmaceutical patents, it provides a list of patents associated with olaparib. However, it does not mention the number of active patents. It is worth noting that the information on DrugPatentWatch may require a subscription to access the complete details.
The second source provided is the AstraZeneca Annual Report for 2021. This report includes a section on "Patent Expiries of Key Marketed Products." While it does not provide specific information about the number of active patents for olaparib, it does mention that the composition of matter patent for olaparib in the United States expired in 2014. This suggests that the original patent for olaparib has expired, but there may be other patents related to its formulation, manufacturing processes, or specific uses that are still active.
The third source is a special report by FiercePharma, which discusses the top 15 blockbuster patent expirations in the coming decade. Olaparib is not specifically mentioned in this report.
In conclusion, based on the provided sources, we cannot determine the exact number of active patents for olaparib in the United States. However, it is worth noting that the composition of matter patent for olaparib has expired in 2014 [2].
Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/OLAPARIB
[2] AstraZeneca Annual Report 2021: https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2021/pdf/AstraZeneca_Patent_Expiries_of_Key_Marketed_Products_2021.pdf
[3] FiercePharma: https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade